Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression

Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performin...

Descripción completa

Detalles Bibliográficos
Autores: Llibre Codina, Josep Maria|||0000-0002-7158-6753, Cozzi-Lepri, Alessandro|||0000-0002-6339-919X, Pedersen, Court, Ristola, Matti, Losso, Marcelo, Mocroft, Amanda, Mitsura, Viktar, Falconer, Karolin, Maltez, Fernando, Beniowski, Marek, Vullo, Vincenzo, Hassoun, Gamal, Kuzovatova, Elena, Szlavik, János, Kuznetsova, Anastasiia, Stellbrink, Hans-Jürgen, Duvivier, Claudine, Edwards, Simon, Laut, Kamilla, Paredes, Roger|||0000-0002-6553-691X
Tipo de recurso: artículo
Fecha de publicación:2016
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:254246
Acceso en línea:https://ddd.uab.cat/record/254246
https://dx.doi.org/urn:doi:10.1097/MD.0000000000005020
Access Level:acceso abierto
Palabra clave:Atazanavir
HIV-1
Protease inhibitors: abacavir
Simplification antiretroviral therapy
Descripción
Sumario:Effectiveness data of an unboosted atazanavir (ATV) with abacavir/lamivudine (ABC/3TC) switch strategy in clinical routine are scant. We evaluated treatment outcomes of ATV + ABC/3TC in pretreated subjects in the EuroSIDA cohort when started with undetectable plasma HIV-1 viral load (pVL), performing a time to loss of virological response (TLOVR <50 copies/mL) and a snapshot analysis at 48, 96, and 144 weeks. Virological failure (VF) was defined as confirmed pVL.

Similares en LA Referencia